OTCMKTS:AVDX - Avant Diagnostics Stock Price, News & Analysis

0.00 (0.00 %)
(As of 06/28/2019)
Today's Range
Now: $0.0320
50-Day Range
MA: $0.03
52-Week Range
Now: $0.0320
Volume38,501 shs
Average Volume4,936 shs
Market Capitalization$10.78 million
P/E RatioN/A
Dividend YieldN/A
Avant Diagnostics, Inc., a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers. It owns license and distribution right for OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolOTCMKTS:AVDX



Sales & Book Value

Annual Sales$250,000.00
Book Value$0.01 per share


Net Income$-2,370,000.00


Market Cap$10.78 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AVDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDX and its competitors with MarketBeat's FREE daily newsletter.

Avant Diagnostics (OTCMKTS:AVDX) Frequently Asked Questions

What is Avant Diagnostics' stock symbol?

Avant Diagnostics trades on the OTCMKTS under the ticker symbol "AVDX."

Has Avant Diagnostics been receiving favorable news coverage?

News headlines about AVDX stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Avant Diagnostics earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Avant Diagnostics.

Who are some of Avant Diagnostics' key competitors?

What other stocks do shareholders of Avant Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avant Diagnostics investors own include Bottomline Technologies (EPAY), SYSCO (SYY), American Airlines Group (AAL), American Railcar Industries (ARII), Cray (CRAY), GW Pharmaceuticals PLC- (GWPH), Netflix (NFLX), Extraction Oil & Gas (XOG), Boeing (BA) and BankUnited (BKU).

Who are Avant Diagnostics' key executives?

Avant Diagnostics' management team includes the folowing people:
  • Mr. Jeffrey M. Busch, Exec. Chairman (Age 59)
  • Dr. Michael I. Ruxin, Pres, CEO & Director (Age 73)
  • Mr. Scott VanderMeer, Interim Chief Financial Officer (Age 32)
  • Dr. Glenn D. Hoke Ph.D., Chief Scientific Officer
  • Ms. Rene A. Schena, Chairman & CEO of Arrayit Corp. (Age 56)

How do I buy shares of Avant Diagnostics?

Shares of AVDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avant Diagnostics' stock price today?

One share of AVDX stock can currently be purchased for approximately $0.0320.

How big of a company is Avant Diagnostics?

Avant Diagnostics has a market capitalization of $10.78 million and generates $250,000.00 in revenue each year. Avant Diagnostics employs 2 workers across the globe.View Additional Information About Avant Diagnostics.

What is Avant Diagnostics' official website?

The official website for Avant Diagnostics is http://avantdiagnostics.com/.

How can I contact Avant Diagnostics?

Avant Diagnostics' mailing address is 1050 30TH STREET NW SUITE 107, WASHINGTON DC, 20007. The company can be reached via phone at 708-710-9200 or via email at [email protected]

MarketBeat Community Rating for Avant Diagnostics (OTCMKTS AVDX)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Avant Diagnostics and other stocks. Vote "Outperform" if you believe AVDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel